Literature DB >> 8001022

Patho- and immunobiology of malignant mesothelioma: characterisation of tumour infiltrating leucocytes and cytokine production in a murine model.

H Bielefeldt-Ohmann1, D R Fitzpatrick, A L Marzo, A G Jarnicki, R P Himbeck, M R Davis, L S Manning, B W Robinson.   

Abstract

Malignant mesothelioma (MM) is an aggressive, uniformly fatal serosal tumour, usually associated with asbestos exposure, for which there currently is no effective treatment. In order to gain insight into the mechanism(s) whereby MM might escape immune surveillance, a murine model for MM was used (a) to characterise the tumour-infiltrating lymphocytes (TIL) and macrophages (TIM) phenotypically, (b) to examine systemic immune recognition of MM, and (c) to examine the possible influence of tumour-derived cytokines on systemic and local pathobiological manifestations of MM. A profound down-regulation of lymphocyte surface markers, known to be involved in T cell activation, was found in TIL. Likewise, although TIM were present in large numbers, their expression of MHC class II antigen and integrins was weak or absent, suggestive of altered functional activity. Significant amounts of cytokines, in particular transforming growth factor beta, interleukin-6 (IL-6), IL-1 and tumour necrosis factor were produced during the course of MM tumour development-directly by the MM cells and/or indirectly in response to tumour growth. These factors may contribute both to derangement of antitumour effector mechanisms and to the clinical and pathological manifestations of the disease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8001022     DOI: 10.1007/BF01534421

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  44 in total

1.  Characterization of a monoclonal antibody directed against the murine B lymphocyte receptor for IgE.

Authors:  M Rao; W T Lee; D H Conrad
Journal:  J Immunol       Date:  1987-03-15       Impact factor: 5.422

2.  Transforming growth factor type beta induces monocyte chemotaxis and growth factor production.

Authors:  S M Wahl; D A Hunt; L M Wakefield; N McCartney-Francis; L M Wahl; A B Roberts; M B Sporn
Journal:  Proc Natl Acad Sci U S A       Date:  1987-08       Impact factor: 11.205

3.  Long-term inhibition of tumor growth by tumor necrosis factor in the absence of cachexia or T-cell immunity.

Authors:  M N Teng; B H Park; H K Koeppen; K J Tracey; B M Fendly; H Schreiber
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-01       Impact factor: 11.205

4.  Isolation of monoclonal antibodies specific for IL-4, IL-5, IL-6, and a new Th2-specific cytokine (IL-10), cytokine synthesis inhibitory factor, by using a solid phase radioimmunoadsorbent assay.

Authors:  T R Mosmann; J H Schumacher; D F Fiorentino; J Leverah; K W Moore; M W Bond
Journal:  J Immunol       Date:  1990-11-01       Impact factor: 5.422

5.  Preferential binding of Chlamydia trachomatis to subsets of human lymphocytes and induction of interleukin-6 and interferon-gamma.

Authors:  D R Fitzpatrick; J Wie; D Webb; R Bonfiglioli; I D Gardner; J D Mathews; H Bielefeldt-Ohmann
Journal:  Immunol Cell Biol       Date:  1991-10       Impact factor: 5.126

6.  Integrin regulation of leukocyte inflammatory functions. CD11b/CD18 enhancement of the tumor necrosis factor-alpha responses of monocytes.

Authors:  S T Fan; T S Edgington
Journal:  J Immunol       Date:  1993-04-01       Impact factor: 5.422

7.  Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality.

Authors:  M R Pinsky; J L Vincent; J Deviere; M Alegre; R J Kahn; E Dupont
Journal:  Chest       Date:  1993-02       Impact factor: 9.410

8.  Transforming growth factor-beta: antisense RNA-mediated inhibition affects anchorage-independent growth, tumorigenicity and tumor-infiltrating T-cells in malignant mesothelioma.

Authors:  D R Fitzpatrick; H Bielefeldt-Ohmann; R P Himbeck; A G Jarnicki; A L Marzo; B W Robinson
Journal:  Growth Factors       Date:  1994       Impact factor: 2.511

9.  The CD3-gamma and CD3-delta subunits of the T cell antigen receptor can be expressed within distinct functional TCR/CD3 complexes.

Authors:  B Alarcón; S C Ley; F Sánchez-Madrid; R S Blumberg; S T Ju; M Fresno; C Terhorst
Journal:  EMBO J       Date:  1991-04       Impact factor: 11.598

10.  Two types of mouse helper T cell clone. III. Further differences in lymphokine synthesis between Th1 and Th2 clones revealed by RNA hybridization, functionally monospecific bioassays, and monoclonal antibodies.

Authors:  H M Cherwinski; J H Schumacher; K D Brown; T R Mosmann
Journal:  J Exp Med       Date:  1987-11-01       Impact factor: 14.307

View more
  13 in total

1.  Establishment of permanent cell lines purified from human mesothelioma: morphological aspects, new marker expression and karyotypic analysis.

Authors:  Marie-Marthe Philippeaux; Jean-Claude Pache; Sophie Dahoun; Marc Barnet; John-Henri Robert; Jacques Mauël; Anastase Spiliopoulos
Journal:  Histochem Cell Biol       Date:  2004-09-15       Impact factor: 4.304

2.  A multifunctional mesothelin antibody-tagged microparticle targets human mesotheliomas.

Authors:  Sherrill L Macura; Jedd M Hillegass; Jeremy L Steinbacher; Maximilian B MacPherson; Arti Shukla; Stacie L Beuschel; Timothy N Perkins; Kelly J Butnor; Melissa J Lathrop; Mutlay Sayan; Khan Hekmatyar; Douglas J Taatjes; Risto A Kauppinen; Christopher C Landry; Brooke T Mossman
Journal:  J Histochem Cytochem       Date:  2012-06-21       Impact factor: 2.479

Review 3.  Malignant mesothelioma: new insights into tumour biology and immunology as a basis for new treatment approaches.

Authors:  J W Upham; M J Garlepp; A W Musk; B W Robinson
Journal:  Thorax       Date:  1995-08       Impact factor: 9.139

4.  Inflammatory Cytokines Contribute to Asbestos-Induced Injury of Mesothelial Cells.

Authors:  Milena Marques Pagliarelli Acencio; Barbara Soares; Evaldo Marchi; Carlos Sergio Rocha Silva; Lisete Ribeiro Teixeira; V C Broaddus
Journal:  Lung       Date:  2015-06-10       Impact factor: 2.584

5.  Inflammation precedes the development of human malignant mesotheliomas in a SCID mouse xenograft model.

Authors:  Jedd M Hillegass; Arti Shukla; Sherrill A Lathrop; Maximilian B MacPherson; Stacie L Beuschel; Kelly J Butnor; Joseph R Testa; Harvey I Pass; Michele Carbone; Chad Steele; Brooke T Mossman
Journal:  Ann N Y Acad Sci       Date:  2010-08       Impact factor: 5.691

6.  Interleukin-6 involvement in mesothelioma pathobiology: inhibition by interferon alpha immunotherapy.

Authors:  H Bielefeldt-Ohmann; A L Marzo; R P Himbeck; A G Jarnicki; B W Robinson; D R Fitzpatrick
Journal:  Cancer Immunol Immunother       Date:  1995-04       Impact factor: 6.968

7.  Inflammation-Related IL1β/IL1R Signaling Promotes the Development of Asbestos-Induced Malignant Mesothelioma.

Authors:  Yuwaraj Kadariya; Craig W Menges; Jacqueline Talarchek; Kathy Q Cai; Andres J Klein-Szanto; Ralph A Pietrofesa; Melpo Christofidou-Solomidou; Mitchell Cheung; Brooke T Mossman; Arti Shukla; Joseph R Testa
Journal:  Cancer Prev Res (Phila)       Date:  2016-03-02

8.  Expression of cancer-associated molecules in malignant mesothelioma.

Authors:  Ben Davidson
Journal:  Biomark Insights       Date:  2007-05-30

9.  Identification of novel autoantibodies for detection of malignant mesothelioma.

Authors:  Xufei Zhang; Weike Shen; Xiaomin Dong; Jiangping Fan; Lixia Liu; Xu Gao; Kemp H Kernstine; Li Zhong
Journal:  PLoS One       Date:  2013-08-19       Impact factor: 3.240

10.  Asbestos Induces Oxidative Stress and Activation of Nrf2 Signaling in Murine Macrophages: Chemopreventive Role of the Synthetic Lignan Secoisolariciresinol Diglucoside (LGM2605).

Authors:  Ralph A Pietrofesa; Anastasia Velalopoulou; Steven M Albelda; Melpo Christofidou-Solomidou
Journal:  Int J Mol Sci       Date:  2016-03-01       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.